Evaluation of Prognostic Factors for Tubo-ovarian Cancer in France
- Conditions
- Ovarian Cancer
- Registration Number
- NCT05204342
- Lead Sponsor
- University Hospital, Montpellier
- Brief Summary
Evaluation of the following prognostic factors in France, based on national quotation data: volume per center, patient age, geographic distance from a clinical center, delay for chemotherapy,Upfront surgery.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- Female
- Target Recruitment
- 22500
Not provided
Not provided
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To study the prognostic effect of the volume of activity at 5 years To study the prognostic effect of the volume of activity per center on the risk of recurrence
Verify that the therapeutic sequence at 5 years Verify that the therapeutic sequence of primary surgery and secondary chemotherapy is a good prognostic factor for overall and specific survival at 5 years
- Secondary Outcome Measures
Name Time Method Verify that delay in initiation of chemotherapy beyond 4 weeks at 5 years Verify that delay in initiation of chemotherapy beyond 4 weeks after surgery is a poor prognostic element on overall and specific survival at 5 years
Verify that age is a poor prognostic element at 5 years Verify that age is a poor prognostic element for overall and specific survival at 5 years
Verify that geographic distance at 5 years Verify that geographic distance from a clinical center is a poor prognostic element for overall and specific survival at 5 years
Trial Locations
- Locations (1)
Uhmontpellier
🇫🇷Montpellier, France